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Heparin-Induced Thrombocytopenia
DAVID B. BRIEGER, MB, BS, PHD, KOON-HOU MAK, MB, BS,
KANDICE KOTTKE-MARCHANT, MD, PHD, ERIC J. TOPOL, MD, FACC
Cleveland, Ohio
Heparin-induced thrombocytopenia (HIT) is a potentially se-
rious complication of heparin therapy and is being encountered
more frequently in patients with cardiovascular disease as use of
anticoagulant therapy becomes more widespread. Our under-
standing of the pathophysiology of this immune-mediated condi-
tion has improved in recent years, with heparin–platelet factor 4
complex as the culprit antigen in most patients. New sensitive
laboratory assays for the pathogenic antibody are now available
and should permit an earlier, more reliable diagnosis, but their
optimal application remains to be defined. For patients in whom
HIT is diagnosed, immediate discontinuation of heparin infusions
and elimination of heparin from all flushes and ports are man-
datory. Further management of patients with HIT is problematic
at present, as there are no readily available alternative anticoag-
ulant agents in the United States with proven efficacy in acute
coronary disease. The direct thrombin inhibitors appear to be the
most promising alternatives to heparin, when continued use of
heparin is contraindicated, and the results of several multicenter
trials evaluating their application in patients with HIT are
awaited.
(J Am Coll Cardiol 1998;31:1449–59)
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Since it was first used to prevent venous thrombosis in surgical
patients in 1937, heparin has been the anticoagulant therapy of
choice for the prevention and early management of arterial
and venous thromboembolic disease (1). Heparin plays a major
role in cardiovascular therapy; it is the routine anticoagulant
agent used in percutaneous transluminal coronary angioplasty
and coronary artery bypass graft surgery and has confirmed
value in the management of patients with unstable angina (2,3)
and as adjunctive therapy in patients receiving thrombolysis
after myocardial infarction (4). Because of the vast clinical
experience with heparin, physicians are generally well aware of
most of the practical limitations associated with its use, includ-
ing the potential for bleeding and interpatient variability in
anticoagulant response after administration (5). The focus of
this report, however, is one of the potentially most devastating
but least well recognized complications of heparin therapy—its
propensity to cause thrombocytopenia with associated throm-
bosis. With the more frequent use of heparin in recent years,
the prevalence of this potentially catastrophic complication has
prominently increased (Fig. 1).
Frequency of Thrombocytopenia
Approximately 10% to 20% of patients will develop a
transient mild thrombocytopenia after 1 to 4 days of heparin
therapy. The platelet count rarely goes below 100,000/ml, often
becomes normal despite further heparin administration and is
generally without clinical sequelae. This benign form of
heparin-induced thrombocytopenia (HIT), attributed to a di-
rect interaction between administered heparin and circulating
platelets, is classified as HIT type I (6) (Table 1).
The more sinister form of HIT generally develops after 5 to
10 days (mean 7 to 8) of heparin therapy. This form is antibody
mediated, can be associated with potentially devastating
thromboembolic sequelae and is classified as HIT type II and
is the topic of this report. A recent prospective, randomized
study of 665 patients receiving either subcutaneous unfraction-
ated or low molecular weight (LMW) heparin for thrombo-
prophylaxis after hip surgery reported a frequency rate of HIT
of 2.7% in patients receiving unfractionated heparin and 0% in
patients receiving LMW heparin. HIT was defined as a de-
crease in the platelet count ,150,000/ml occurring at least 5
days after beginning heparin therapy, accompanied by heparin-
dependent antiplatelet antibodies detected by the sensitive
14C-serotonin release assay (7).
Unfortunately there have not been any comparably de-
signed, prospective, large-scale trials investigating the fre-
quency of HIT in patients receiving full-dose intravenous
heparin. However, pooled analyses derived from less rigorous
prospective studies suggest that HIT becomes more common
after full-dose intravenous heparin than after subcutaneous
heparin (8,9). The reported frequency of HIT type II in this
patient group ranges from 0% to 30%, reflecting the varying
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patient groups studied, different types of heparin used and
varying definitions of thrombocytopenia (10).
Although HIT appears to be more common after adminis-
tration of larger doses of heparin, it may still occur after
exposure to very small quantities of the drug. The condition
has been described in patients receiving small amounts of
heparin in flush solutions used to maintain the patency of
indwelling peripheral catheters (11–14) and in patients with
heparin-coated pulmonary artery catheters (15).
A number of investigators (16–20) have observed that
patients previously exposed to heparin develop HIT earlier
after institution of heparin therapy compared with those with
no previous exposure, suggestive of an anamnestic response,
although the objective evidence for the existence of immuno-
logic memory in these patients is not strong (see later discus-
sion). The small, prospective studies to date have not demon-
strated an association between previous treatment with
heparin and an increased likelihood of developing HIT (21),
and it is anticipated that ongoing, adequately sized, prospective
trials will provide a clearer perspective of the impact of
previous exposure to heparin on the frequency of this syn-
drome.
Most prospective studies comparing porcine mucosal with
bovine lung heparin have reported a greater frequency of HIT
among patients receiving the latter (8,21,22). Individual
batches of heparin may have an increased propensity to cause
thrombocytopenia even when derived from the same source,
giving rise to “epidemics” of HIT (23).
Thrombocytopenia and thrombosis are not unique to hep-
arin and have also been described after administration of other
sulfated glycosaminoglycans such as LMW heparin, pentosan
polysulfate and chondroitin sulfate (24,25). The frequency with
which it occurs appears to be directly related to the size and
degree of sulfation of the molecule (25).
Frequency of Thromboembolic Events
There is conflicting information in the published data
concerning the frequency of thromboembolic events in pa-
tients with HIT. Early retrospective studies reported a fre-
quency rate .60%, although this may have reflected the fact
that the condition was often not recognized before complica-
tions occurred (26–28).
In prospective studies of HIT, only small numbers of
patients have developed thrombotic complications (29). When
data from the adequately designed studies are pooled, the risk
of thrombosis in patients with HIT is estimated at 30% (30).
The frequency may vary dramatically with the baseline risk of
thrombosis in the patient group. In the study of patients
receiving heparin for thromboprophylaxis after hip surgery, 8
(88.9%) of the 9 patients with HIT had one or more throm-
botic events as compared with 117 (17.8%) of the 656 patients
without HIT (7). Data from a recent, carefully performed,
retrospective study suggest that the risk of thrombotic events
may persist for several weeks after exposure to heparin (31). In
this study of 62 patients diagnosed initially with isolated HIT,
.50% experienced thrombotic complications over the ensuing
30 days.
Pathophysiology
Type II HIT is an immune-mediated reaction most com-
monly caused by an immunoglobulin (Ig) G antibody that
binds to platelets in the presence of heparin and causes platelet
activation (Fig. 2). Heparin-dependent IgM and IgA antibod-
ies have also been described, and recent evidence suggests that
they too may induce type II HIT (32).
The antigen. Despite the important role of heparin in
initiating and sustaining the syndrome, it has not been possible
Abbreviations and Acronyms
ELISA 5 enzyme-linked immunosorbent assay
HIPA 5 heparin-induced platelet aggregation
HIT 5 heparin-induced thrombocytopenia
Ig 5 immunoglobulin
LMW 5 low molecular weight
PF4 5 platelet factor 4
Figure 1. Incidence of HIT as determined by clinical suspicion and
positive in vitro heparin-dependent platelet aggregation assays per-
formed at the Cleveland Clinic Foundation from 1991 to 1996 (data for
1996 were collected from January through October).
Table 1. Distinguishing Characteristics of the Two Types of
Heparin-Induced Thrombocytopenia
Type I Type II
Frequency 10–20% 2–30%
Timing of onset 1–4 days 5–10 days
Nadir platelet count 100,000/ml 30,000–55,000/ml
Antibody mediated No Yes
Thromboembolic sequelae None 30–80%
Hemorrhagic sequelae None Rarely
Management Observe Cessation of heparin,
alternative anticoagulation,
additional therapy
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to directly demonstrate an interaction between the antibody
and heparin alone. In 1992, it was shown that the majority of
antibodies generated in HIT recognized a complex between
heparin and platelet factor 4 (PF4) (33–35). The antibody is
not specific for heparin, but reacts with other sulfated polysac-
charides bound to PF4. This cross reactivity increases with size
and negative charge of the polysaccharide (36).
In up to 25% of cases the antibody does not recognize the
polysaccharide–PF4 complex, indicating that antigens other
than PF4 are responsible for some cases of HIT (37). These
antigens remain unidentified.
The antibody response. The heparin-dependent IgG gen-
erally becomes detectable after 5 to 7 days of heparin therapy.
Patients preexposed to heparin may develop HIT sooner after
institution of therapy than those receiving heparin for the first
time, suggestive of an anamnestic response. However, almost
all of these reported events have occurred within days to weeks
of the index exposure (16–20,38,39), when the heparin-
associated IgG is usually still detectable in the circulation and
is presumably responsible for the thrombocytopenia. It is
noteworthy that patients with cardiac disease requiring percu-
taneous or surgical interventions have frequently been exposed
to heparin within this time frame. One case of recurrent HIT
(40), documented years after the initial episode, reported a
time course comparable to the index event, consistent with the
mounting of a second primary immune response and absence
of immunologic memory.
Platelet activation. In HIT, IgG binds to the antigenic
complex (usually heparin–PF4) on the platelet surface, with
the activation of platelets through the Fc receptor (FcgRII)
(36,41). Platelets from patients with HIT express increased
numbers of Fc receptors on their surface. These platelets show
an increased tendency to aggregate in the presence of heparin-
dependent antibodies (42). Recent evidence suggests that
genetic polymorphisms of the Fc receptor, specifically the
presence of the Fcg RIIAHis131 allele, may be associated with
a predisposition to HIT (43). Binding of the HIT-IgG to the Fc
receptor results in platelet granule release, thromboxane gen-
eration, strong platelet aggregation and microparticle release
(see late discussion) (44,45).
A recent report suggests that both IgM and IgA can induce
HIT complicated by thrombosis (32). As platelets are not
known to carry a receptor for IgM or IgA Fc, this suggests that
in these instances, platelet activation occurs through Fc-
independent mechanisms.
Activation of coagulation. Depletions in the levels of the
coagulation factor inhibitors protein C, heparin cofactor II and
antithrombin III have been reported in patients during the
thrombocytopenic phase of HIT and normalize after resolu-
tion of the thrombocytopenia (28). Disseminated intravascular
coagulation is also seen, although not commonly (21). The
heparin-associated platelet activation and aggregation conse-
quent on production of the antibody are associated with the
generation of platelet-derived microparticles with procoagu-
lant activity (46), and this, possibly together with endothelial
activation (see later discussion), may contribute to the gener-
alized activation of the coagulation cascade.
Endothelial cell activation. In vitro studies have provided
suggestive evidence that endothelial cell activation may con-
tribute to the pathophysiologic sequelae of HIT. Serum sam-
ples from patients with HIT have increased amounts of IgG,
IgM and IgA on endothelial cells, stimulating the release of
tissue factor (47). The binding of both IgG and IgM HIT
antibodies to endothelial cells requires the presence of PF4 but
not heparin (41). Binding is reduced when the cells are
incubated with heparinase, suggesting that this interaction is
mediated in part by endogenous heparin-like molecules such
as heparan sulfate found on the surface of endothelial cells
(48).
However, the in vivo contribution of endothelial cell acti-
vation and procoagulant activity to the thrombotic sequelae of
HIT has been challenged for several reasons (29). First, the
Figure 2. Pathophysiology of HIT syndrome. In sus-
ceptible subjects, heparin bound to PF4 results in an
antibody response. An IgG antibody directed against
a heparin–PF4 complex binds platelets through the
Fc receptor. This results in platelet activation and
microparticle formation. Platelet-rich thrombi form
at sites of preexisting pathology (arterial thrombotic
events in patients with atherosclerotic vascular dis-
ease) or sites of endothelial injury (e.g., deep venous
thrombosis in patients undergoing orthopedic sur-
gery).
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risk of thrombosis generally decreases quickly after cessation
of heparin, despite the fact that the antibody can often be
demonstrated for several weeks (49). In addition, thromboem-
boli tend to be located at sites of vascular injury rather than
being diffusely distributed throughout the vascular tree (17,28),
suggesting that endothelial disruption rather than integrity
may provide the focus for the thrombogenic response.
Clinical Presentation of HIT
Thrombocytopenia. Thrombocytopenia usually commences
between 6 and 12 days after instituting therapy (30). The
platelet count typically drops to between 30,000 and 55,000/ml,
a feature that distinguishes HIT from other forms of drug-
induced immune thrombocytopenia, which are typically asso-
ciated with more precipitous falls in the platelet count (30).
However, counts as low as 5,000/ml have been reported in
patients with HIT (26).
Thrombosis. Thromboembolic events are always accompa-
nied by a fall in the platelet count, usually to thrombocytopenic
levels (9), and the mean platelet count in patients with HIT
who develop thromboses tend to be lower than that in those
who do not develop thromboses (31). However, in any individ-
ual patient the risk of a thrombotic event cannot be pre-
dicted from the platelet count, and complications in the
absence of absolute thrombocytopenia have been reported
(50–52). The most common thrombotic complications attrib-
uted to HIT have been arterial events resulting in lower limb
ischemia, cerebrovascular accident or myocardial infarction
(19,26,28,49,51,53–55). Arterial thrombotic episodes at many
other sites have also been reported, including arterial graft
thrombosis (26,52,55,56), upper limb arterial thrombosis
(26,57), renal artery thrombosis (18), mesenteric ischemia (49),
spinal artery thrombosis (44), aortic thrombosis (53,58),
splenic infarction (59), thrombosis of cardiac chambers (60)
and adrenal thrombosis resulting in acute adrenal insufficiency
(61). These events, when they occur, often have serious
sequelae; it has been estimated that patients with HIT and
arterial thrombosis have a mortality rate of ;30% and have a
risk of leg amputation of ;20% (20).
Extension of venous thrombosis with recurrent pulmonary
embolism has frequently been described in patients after onset
of HIT (62–64). Venothrombotic events may be severe—for
instance, the progression of venous thrombosis to phlegmasia
cerulea dolens, in some cases requiring amputation (53,56).
Other reported venous thrombotic events include renal vein
thrombosis (13), cerebral venous thrombosis (27) and throm-
bosis of the upper limb veins (53). Thromboses frequently
occur at multiple sites (65,66), and arterial and venous events
may occur together (28,54).
Predictors of risk and nature of thrombotic event. A
number of studies have suggested that thrombotic events are
more likely to occur at sites of preexisting pathology. In one
reported series of 25 patients developing HIT and arterial or
venous thrombosis, 19 had passage of an arterial or venous
catheter or an intraaortic balloon counterpulsation device in
the affected extremity (17). Similarly, Singer et al. (55) re-
ported a series of four patients who developed thrombotic
complications of HIT requiring limb amputation after cardio-
pulmonary bypass, all of whom had previous intravascular
devices at those sites. A recent detailed review of 53 patients
with HIT identified an association between cardiovascular
disease (myocardial infarction or cardiovascular surgery) and
arterial thrombotic events. These investigators also noted a
recent operation to be strongly associated with venous throm-
bosis (28). In patients receiving heparin after a cerebrovascular
accident, 7 of 21 patients with a significant fall in the platelet
count experienced an arterial thrombotic event, either exten-
sion of their cerebrovascular accident or a myocardial infarc-
tion. There were no venous thrombotic events reported in this
patient group (51).
Less common manifestations. Premonitory symptoms. Skin
necrosis occurring at sites of subcutaneous administration,
thought to be mediated by microvascular thrombosis (67), may
precede the development of thrombocytopenia (68,69). Ad-
ministration of intravenous heparin to patients with these
lesions may be catastrophic, with the development of severe
systemic thromboembolic complications (38,67,70). Acute sys-
temic reactions (resembling acute febrile transfusion reac-
tions) to intravenous heparin bolus therapy have been de-
scribed in patients with preexisting dermal lesions at sites of
subcutaneous heparin administration. There have also been
several reports of unexplained abdominal or limb pain, thought
to be ischemic in origin, heralding thrombosis (54,58).
Heparin resistance. Impending events may also be heralded
by the development of increasing heparin requirements to
maintain adequate anticoagulation (26,62,71). Although the
mechanism underlying this heparin resistance has not been
elucidated, it may reflect platelet release of PF4, which has
heparin-neutralizing properties (72), or it may be mediated by
the production of platelet-derived microparticles with proco-
agulant activity (46,73).
Hemorrhage. Despite the presence of thrombocytopenia,
hemorrhage is less common than thromboembolic complica-
tions in these patients, and there is no relation between the
degree of thrombocytopenia and the likelihood of bleeding
complications (49). However, when they occur, bleeding com-
plications may be severe and have included intracranial (74),
retroperitoneal (75), gastrointestinal (59) or adrenal hemor-
rhage (76,77). Patients undergoing bypass surgery may be more
prone to the bleeding manifestations of HIT (59).
Impact of HIT on patients with cardiovascular disease.
There have been several prospective studies investigating the
frequency of HIT in patients receiving heparin in the coronary
care unit or for coronary artery disease. The reported com-
bined frequency of HIT types I and II ranged from 0% to 24%,
and none of the patients reported in these studies experienced
thrombotic events (21,39,78,79). Several early reports cited
patients who developed deep venous thrombosis or pulmonary
embolus associated with thrombocytopenia while receiving
heparin for thromboprophylaxis after acute myocardial infarc-
tion (27,80,81). Heparin therapy has been used more aggres-
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sively in recent years, with the recognition of the integral role
of intracoronary thrombus formation in the development of
the acute coronary syndromes. In a recent analysis of 1,000
patients enrolled in four consecutive prospective thrombolytic
trials, thrombocytopenia defined as either platelet counts
,100,000/ml or less than half baseline, occurred in 16.4% of
patients, and these patients had a higher in-hospital mortality
rate and a more complicated hospital course than patients
without thrombocytopenia (82). In a significant number of
these patients the fall in the platelet count occurred after 5 to
10 days (median 4) of heparin therapy, suggesting that HIT
contributed to some of the detected thrombocytopenia.
Patients undergoing bypass surgery for coronary artery
disease have usually been exposed to heparin previously and
require large doses for thromboprophylaxis during bypass
surgery. Retrospective studies have reported a frequency of
HIT in these patients of between 0.5% and 1.9% (55,59,83). In
one of these reports, late recognition of the condition (i.e.,
postoperatively) was associated with a high frequency of
bleeding (53%), arterial and venous thromboembolic compli-
cations (44%) and death (33%) (59).
Heparin is also routinely used during percutaneous coro-
nary interventions, and these patients, too, have usually been
exposed to the drug previously. Several patients have been
described in whom an acute myocardial infarction occurred
during coronary angioplasty in association with the abrupt
onset of HIT (84,85). An association between femoral artery or
venous punctures for cardiac catheterization, angiography or
insertion of intraaortic balloon counterpulsation devices and
arterial or venous thrombosis in the instrumented limbs of
patients with HIT has been reported (17).
Diagnosis
HIT should be suspected in any patient who develops
thrombocytopenia (,150,000/ml) or a 50% or greater fall in
the platelet count after 5 days of heparin therapy (7). The
platelet count should be repeated and the blood film examined
to exclude platelet clumping causing pseudothrombocytopenia
(86). After confirmation of the low platelet count, the diagno-
sis of HIT may be made according to the following criteria: 1)
occurrence of thrombocytopenia during heparin administra-
tion; 2) exclusion of other causes of thrombocytopenia such as
infection, drugs and autoimmune thrombocytopenia; 3) reso-
lution of thrombocytopenia after cessation of heparin therapy;
and 4) demonstration of a heparin-dependent platelet anti-
body by an in vitro test (6). Criteria 1 and 2 only are required
for the diagnosis of HIT type I. As in most hospitals, in vitro
confirmation requires analysis of samples in a reference labo-
ratory (see later discussion); the initial diagnosis of HIT is
often made on clinical grounds (criteria 1, 2 and 3).
In the absence of thrombocytopenia, HIT should also be
considered if a patient receiving heparin experiences a new
thrombosis or develops heparin resistance or (rarely) skin
necrosis at sites of heparin administration.
Laboratory Studies for the
Heparin-Dependent Platelet Antibody
A variety of laboratory tests for the detection of heparin-
dependent platelet antibodies have been described (33,45,
87,88). The most widely used is the platelet aggregation test,
which measures the aggregation of normal donor platelets by
patient serum or plasma in the presence of heparin. This test is
popular because it is simple, inexpensive and based on a
technique that is already in use in most hemostatic laboratories
and can provide a result within 2 to 3 h (10). Although it has
a specificity of ;90%, the sensitivity is reported to be between
30% and 50% (37,89–91), which, in the view of some investi-
gators, limits its clinical usefulness (30). However, when per-
formed under optimal conditions, with appropriate positive
and negative controls, using donor platelets from individuals
known to be highly reactive to the antibody, the sensitivity of
the test is reported to exceed 80% (88). Using washed platelets
(prepared as for the two-point 14C-serotonin release assay [see
later discussion]) in place of platelet-rich plasma for the
aggregation assay may increase its sensitivity and specificity
(heparin-induced platelet aggregation [HIPA] test) (92).
The currently accepted reference standard for the labora-
tory diagnosis of HIT is the two point 14C-serotonin release
assay (45). In this assay, radiolabeled, washed platelets from
reactive donors are incubated with heat-treated patient serum
in the presence of heparin. The test is positive if 14C-serotonin
release occurs at therapeutic (0.1 U/ml) but not high (100 U/ml)
heparin concentrations. It is technically demanding, uses ra-
dioactivity and is timing consuming, and therefore usually
performed in a reference laboratory and used to confirm rather
than to make the diagnosis of HIT (93).
A number of investigators have adapted the enzyme-linked
immunosorbent assay (ELISA) technique to devise diagnostic
tests for HIT (33,87,91). The most recent of these uses
immobilized PF4 bound to heparin as a target for the HIT
antibody (33). Initial studies reported PF4 ELISA to be at least
as sensitive as both the 14C-serotonin release and HIPA assays,
although discrepant results occur in up to 25% of patients,
indicating that the different assays recognize different patient
cohorts (37,94). Two recent studies evaluating this assay in
patients after cardiopulmonary bypass surgery have reported
the heparin-associated antibody to be detectable in .50% of
patients by the time of hospital discharge (95,96). The pres-
ence of antibody was not predictive of either thrombocytope-
nia or thromboembolic complications (96), suggesting that the
increased sensitivity may be of limited clinical utility in this
setting. Further evaluation of this assay will be required before
its integration into routine clinical practice.
Prevention
The most important principle of prevention is to minimize
the exposure to heparin. In patients with established venous
thrombosis, early commencement of warfarin shortens the
duration of heparin therapy, thus minimizing the likelihood of
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developing thrombocytopenia without affecting efficacy (97).
Most investigators stress the importance of maintaining a high
index of suspicion and performing regular platelet counts in all
patients receiving heparin therapy (6,30). This has been pred-
icated on the retrospective observation that prompt diagnosis
of the condition with abrupt withdrawal of the drug can
substantially reduce the complication and mortality rates (49).
However, in a more recent retrospective analysis (31), patients
with a diagnosis of HIT had a subsequent 30-day risk of
thrombosis .50%, despite cessation of heparin therapy with or
without institution of warfarin therapy, suggesting that addi-
tional alternative anticoagulant therapy may be necessary in
this patient group.
Treatment
HIT type I. Asymptomatic patients developing mild throm-
bocytopenia in the absence of the heparin-dependent antibody
do not require specific treatment. However, it may be difficult
to distinguish this condition from early type II; these patients
should be closely monitored, and if there is any doubt, heparin
should be discontinued.
HIT type II. In patients who develop thrombocytopenia
with a positive laboratory test for the heparin-dependent
antibody, the cornerstone of therapy is the absolute discontin-
uation of heparin. It is imperative that all potential sources of
heparin be avoided, a task that can be difficult given the
ubiquity of the drug in the hospital setting. Platelet transfu-
sions are not recommended, both because bleeding complica-
tions are uncommon and thrombotic events can follow the
transfusions (62,98). Once heparin is discontinued, the platelet
count should begin to increase within 24 to 48 h and reach
normal levels by 4 to 5 days (30). For patients with confirmed
venous or arterial thrombosis, the selection of substitute
anticoagulant therapy is particularly problematic in the United
States at present, as there is currently no readily available,
effective, alternative antithrombotic drug. If long-term antico-
agulation is required, treatment with warfarin should be com-
menced. However, warfarin may precipitate venous limb gan-
grene in patients with deep venous thrombosis complicating
HIT by producing protein C deficiency without simultaneous
inhibition of thrombin generation, so it should not be admin-
istered without concomitant use of a rapidly acting anticoagu-
lant agent (99).
Of the alternative anticoagulant therapies that have been
tried in patients requiring early management for the thrombo-
embolic manifestations of HIT, LMW heparin, the LMW
heparinoid Orgaran and the defibrinogenating agent ancrod
have been used most extensively. In the setting of acute
coronary disease, however, the most promising therapy is
direct thrombin inhibition.
Direct thrombin inhibitors. After anecdotal reports of the
successful use of the prototypic direct thrombin inhibitor
hirudin in the management of patients with HIT (100,101), a
prospective, open-label evaluation of this drug in achieving
therapeutic levels of anticoagulation in patients with HIT is
under way in Europe. In a recent preliminary report on the first
82 patients enrolled in this study, effective anticoagulation was
achieved in the majority. Five patients (6%) had new throm-
boembolic complications, 7 (8%) had major bleeding events
and 3 (4%) had to undergo limb amputation. Six patients died,
but all fatal events were due to aggravation of underlying
medical problems; none were causally related to hirudin (102).
In the United States, the cost of hirudin, together with a
general perception that it performed less well than expected in
two recent large-scale trials in patients with acute coronary
syndromes (103,104), has discouraged manufacturers from
pursuing its further development for management of patients
with acute coronary disease. However, these studies did con-
firm the safety and antithrombotic efficacy of direct thrombin
inhibition (105), features which, together with the lack of cross
reactivity with the heparin-dependent antibody, render the
direct thrombin inhibitors potentially ideal alternatives for
HIT.
The synthetic thrombin inhibitor argatroban has been suc-
cessfully used in patients with HIT (106). One center recently
reported a reduction in mortality from 32% in untreated
historical control subjects to 18% in argatroban-treated pa-
tients with HIT (107). Open-label, prospective studies evalu-
ating argatroban in patients with a history or current evidence
of HIT undergoing percutaneous coronary intervention or
peripheral vascular procedures are nearing completion in the
United States, and it is hoped that the margin of benefit will be
sufficient to encourage the further development and marketing
of this agent for the management of this condition.
LMW heparins (Fig. 3). Several retrospective reports have
shown that LMW heparin administered to patients with HIT in
the absence of cross reactivity, as detected by in vitro platelet
aggregation assay, results in a favorable outcome, whereas if
cross reactivity is demonstrated, there is a significant likelihood
of further thrombotic events (54,108). However, when sera
Figure 3. Structural characteristics of unfractionated heparin, LMW
heparin and LMW heparinoids. Unfractionated and LMW heparins
are derived from repeating disaccharide subunits of uronate-
glucosamine. LMW heparinoid consists of a mixture of heparan
sulfate, which is structurally similar to but less heavily sulfated than
heparin, chondroitin sulfate and dermatan sulfate. The latter two
saccharides are derived from repeating disaccharide subunits of
uronate-galactosamine. EC 5 endothelial cell(s).
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from patients with HIT are tested for reactivity with LMW
heparin using the sensitive 14C-serotonin release or HIPA
assays, cross reactivity with unfractionated heparin approaches
100% (37,109). For this reason, LMW heparin therapy should
be avoided in patients with HIT (30). However, in the absence
of readily available alternatives, if the in vitro platelet aggre-
gation assay does not demonstrate cross reactivity with LMW
heparin, it is currently common practice to administer LMW
heparin to these patients and monitor them closely for further
thrombotic events, persisting thrombocytopenia or the devel-
opment of a LMW heparin-dependent antiplatelet antibody
(10,110) (Fig. 3).
LMW heparinoid. Although it belongs to the same family of
drugs as heparin and LMW heparin, the LMW heparinoid
Orgaran, which is presently available for compassionate use in
the United States, differs from the LMW heparins in a number
of ways (Fig. 3C). It is a mixture of sulfated glycosaminoglycans
derived from porcine intestinal mucosa and consists of 84%
heparan sulfate, 12% dermatan sulfate and 4% chondroitin
sulfate (111). In contrast to LMW heparin, each component of
Orgaran is structurally distinct from unfractionated heparin
(Fig. 3). As a consequence, it has relatively low cross reactivity
(10% to 20%) with the heparin-dependent antibody, as deter-
mined by aggregation, serotonin release or HIPA assays
(37,85,112). In an overview of 230 patients with HIT treated
with Orgaran (85), 93% of patients were considered to have
responded adequately to the drug during the treatment period.
Approximately 26% of the patients died, but in only 7 patients
(3%) was the death deemed directly attributable to Orgaran.
The use of Orgaran in patients undergoing open heart surgery
is potentially limited by the fact that its anticoagulant effect
cannot be neutralized by protamine sulfate. Consistent with
this, of 19 patients undergoing cardiopulmonary bypass surgery
with Orgaran in place of heparin, 11 bled more than expected.
Although Orgaran has been demonstrated to be effective in the
prevention and treatment of venous thrombosis (113,114),
experience in patients with acute coronary disease or in those
requiring coronary or vascular surgery outside the contexts
cited earlier is limited. Nevertheless, in Canada and Australia,
where the drug has been licensed for clinical use for some
years, most authorities currently regard Orgaran as the treat-
ment of choice for patients with HIT (10) (T. Warkentin,
personal communication, 1997).
Ancrod. This is a rapidly acting defibrinogenating agent
derived from the Malayan pit viper; it is immunologically
distinct from heparin and does not cause thrombocytopenia. It
acts by cleaving fibrinopeptide A from fibrinogen, producing
an unstable product that is rapidly removed from the circula-
tion (115). It may be administered intravenously or subcuta-
neously and is monitored by measuring the fibrinogen concen-
tration. Although ancrod has been used successfully in a
number of patients with thrombotic complications of HIT
(116–118), it is not readily available in the United States.
Furthermore, it does not suppress thrombosis in all cases (T.
Warkentin, personal communication, 1997) and should there-
fore be considered a less favorable alternative in these pa-
tients.
Antiplatelet agents. In the absence of controlled, prospec-
tive data, antiplatelet agents such as aspirin, dipyridamole or
dextran have been recommended empirically as adjunctive
therapy after cessation of heparin in patients with HIT, both in
the presence and absence of thrombosis (6,16,49,119). Anti-
platelet agents have also been given with continued adminis-
tration of heparin in patients in whom cessation of the
anticoagulant agent was believed to be undesirable. In a series
of 12 patients with HIT requiring urgent open heart surgery
with intraoperative heparin, the preoperative administration of
aspirin and dipyridamole resulted in no postoperative throm-
boembolic events and bleeding in only three patients (59). In
another small study of 9 patients, however, it was found that
although this strategy protected patients from thromboembolic
complications, it did not prevent the thrombocytopenia asso-
ciated with limited heparin reexposure (120). Aspirin is not
consistently effective in inhibiting the heparin-dependent anti-
body in vitro, presumably reflecting the fact that it has an
impact on only one of several pathways of platelet activation
and aggregation (121,122). Furthermore, even when aspirin
does prevent heparin-induced platelet activation in vitro, this
does not necessarily predict its efficacy in vivo (50).
Iloprost, a stable prostacyclin analogue with a circulating
half-life of 15 to 30 min, consistently blocks heparin-dependent
platelet activation and aggregation in vitro (50,123). Intraop-
erative infusion of Iloprost has permitted the uneventful
administration of heparin to patients with a history of HIT
undergoing both vascular and cardiac surgery (124–126). At
higher doses the drug may cause hypotension requiring coad-
ministration of vasopressor support (125). Although, from the
reports cited earlier, this agent showed considerable promise
in this setting, it is unfortunately not currently available in the
United States. The monoclonal antibody to the platelet glyco-
protein IIb/IIIa 7E3 (Reopro) has been shown to prevent
heparin-mediated platelet aggregation induced by HIT plasma
in vitro (127). Furthermore, recent in vitro studies have
demonstrated that Reopro can significantly reduce thrombin
generation initiated by tissue factor (128). Although prelimi-
nary studies from our laboratory and others (129) suggest
Reopro is able to block the heparin-dependent antibody-
induced platelet release reactions, platelets from patients with
Glanzmann’s thrombasthenia lacking the glycoprotein IIb/IIIa
receptor can be activated by HIT IgG (34,130,131), suggesting
that inhibition of this receptor will not give complete protec-
tion against the prothrombotic manifestations of the syn-
drome.
Other therapies. Surgical intervention such as thrombec-
tomy or embolectomy may be indicated for limb salvage
(49,56,124). Insertion of an inferior vena cava filter in patients
with proximal deep venous thrombosis or embolism may
reduce the risk of further emboli, but has been associated with
thrombosis of the inferior vena cava up to the level of the filter
(124). There have been isolated case reports of the adminis-
tration of fibrinolytic agents (streptokinase, urokinase) without
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bleeding complications to patients with HIT with deep venous
thrombosis (132,133), pulmonary emboli (134) and arterial
thrombosis (135).
Small numbers of patients have received plasma exchange
therapy in an attempt to remove the heparin-associated IgG.
After relatively few treatments (ranging from one to six,
generally in association with antiplatelet agents, plasmaphere-
sis has been followed by reversal of the heparin-associated
platelet aggregation abnormality, resolution of thrombocyto-
penia and stabilization of thrombotic phenomena (136–139).
Some preparations of high dose Ig can prevent heparin-
associated platelet activation by HIT sera, presumably by
competitively inhibiting binding of the HIT-IgG to the platelet
Fc receptor (131). Correction of thrombocytopenia after ad-
ministration of intravenous Ig has been reported in several
patients with HIT (30,140).
Readministration of heparin. In patients with heparin-
dependent antibodies, as detected by in vitro aggregation
studies, reexposure to heparin is associated with a high risk of
thrombocytopenia and thrombosis (120). In the majority of
patients, the heparin-induced aggregation will disappear within
several weeks, although persistence for over 2 years has been
documented (49). In some clinical situations, such as cardio-
pulmonary bypass surgery, where anticoagulation is deemed
essential and the safety and efficacy of heparin are well
established, some investigators have advocated awaiting disap-
pearance of the heparin-dependent antibody, as monitored by
in vitro aggregation studies, and then performing the operation
or procedure with full heparinization but without postopera-
tive heparin administration (141). Although anecdotal, this
approach has been successful. However, it may prove danger-
ous in those patients for whom the available in vitro assay is
not sufficiently sensitive to detect a pathophysiologically potent
antibody (89) or for the occasional patient in whom severe HIT
can be provoked by reexposure to heparin.
HIT with thrombosis can recur years after a previous
episode, even when a negative platelet aggregation test has
been confirmed after the initial event (40). In general, patients
with a history of HIT should therefore be advised to avoid
further heparin exposure for life.
Conclusions
HIT is encountered more frequently in the practice of
cardiology as the application of anticoagulant therapy becomes
more generalized. The thrombotic complications of HIT are
associated with significant morbidity and mortality and can
only be prevented by early recognition of the condition. It is
therefore imperative that cardiologists maintain a high index of
suspicion and perform frequent platelet counts in all patients
receiving heparin therapy. Once HIT is diagnosed, heparin
must be stopped immediately and eliminated from all infusion
lines and flushes. In most cases, alternative anticoagulant
therapy should be initiated—a task made difficult at present by
the absence of a readily available alternative anticoagulant
agent with proven efficacy in patients with acute coronary
disease. Several direct thrombin inhibitors are being evaluated
in patients with HIT, and it is hoped that the margin of benefit
will be sufficient to encourage the manufacturers to make this
drug available for the management of this potentially life-
threatening complication of heparin therapy.
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